A firestorm erupted this week in response to the pharmaceutical company Mylan’s sharp increase in the price of its EpiPen, a life-saving treatment for severe allergic reactions. The company quickly backtracked, announcing a rebate plan. Here, three Northeastern faculty members—pharmacist Tayla Rose, healthcare finance expert Steven Pizer, and health policy researcher Gary Young—explain the clinical, economic, and policy implications of the controversy.
Jack Reynolds, dean of the School of Pharmacy, discusses the recent outbreak of fungal meningitis, which was traced back to a compounding pharmacy in Framingham, Mass.
Mansoor Amiji, distinguished professor and chair of pharmaceutical sciences, tracks the drug discovery process, and analyzes how the pursuit of ‘blockbuster’ drugs compares to treating patients with rare illnesses